Laurus Labs signs definitive agreements to acquire majority stake in Richcore
25th Nov 2020

Laurus Labs has signed definitive agreements to acquire a majority stake in Richcore Lifesciences (Richcore). Richcore, a fast-growing biotech company based in Bengaluru with its advanced R&D and manufacturing facilities, develops and manufactures biotech products critical for manufacturing biological drugs. Richcore also helps its global customers to develop and scale-up their bioprocesses by providing contract research, development, and manufacturing services.

This acquisition marks Laurus Labs’ entry into the broader biologics and biotechnology segments, providing the company access to its high growth areas, globally and in India. The company will help and drive Richcore to achieve scale and improve product offerings. With this acquisition, company adds a fourth revenue stream to its three existing divisions - API, Formulations and Synthesis.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.